BioInsights - High throughput viral titering of AAV throughout the production continuum
Aug
4
2022
On demand

High throughput viral titering of AAV throughout the production continuum

Sponsor
High throughput viral titering of AAV throughout the production continuum

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Process development for viral vector manufacturing relies on accurate titers to inform critical decisions. Digital PCR is the established titer method to support AAV manufacturing, but droplet-based methods have historically been challenged by matrix effects and long time to data. Please join us to learn how the Center for Breakthrough Medicines (CBM) has applied nanoplate-based QIAcuity digital PCR technology to achieve accurate titers from multiplexed assays with challenging samples.

What you will learn:

  • How new advances in digital PCR provide more data, across more sample types, faster, and with higher throughput: 
  • Critical factors to consider when choosing automated platforms for AAV viral titer determination 
  • Strategies to efficiently quantify more targets in the same sample 
  • Pushing past common droplet busting matrices to expand testing throughout the AAV process continuum

Kelly Geosits

Research & Development Associate Scientist, Center for Breakthrough Medicine

Kelly Geosits is a Research & Development Associate Scientist at Center for Breakthrough Medicine. Kelly graduated from the University of the Sciences in Philadelphia with a BS in Microbiology in 2014. Her undergraduate research focused on microtubule dynamics in the cytoskeleton. After graduation, she worked on research projects at Hahnemann Hospital through Drexel College of Medicine focusing on paracrine signaling in metastatic pancreatic ductal adenocarcinoma. Kelly had brief sales roles before working at Puresyn, a plasmid DNA manufacturer, where she worked in purification and eventually in quality assurance. She is thrilled to be back in a laboratory research setting focusing on Upstream Process Development for AAV gene therapy.

SPEAKERS

Kelly  Geosits
Kelly Geosits
Research & Development Associate Scientist at Center for Breakthrough Medicine

You might also like